Are Allergy Drops as Effective as Allergy Shots?

For grass pollen, the evidence supports broadly comparable effectiveness. The Nelson et al. 2015 network meta-analysis in the Journal of Allergy and Clinical Immunology: In Practice found a symptom-score standardized mean difference of just 0.01 between sublingual and subcutaneous immunotherapy for grass — a clinically negligible gap. FDA-approved grass tablets also have strong phase-3 trial evidence. Placebo-controlled Cochrane reviews show meaningful symptom reduction for both routes with overlapping confidence intervals. This makes grass one of the allergens where the routes appear most equivalent. That said, individual results vary with adherence, dose, and the full sensitization profile, and at least three years of treatment is needed for durable benefit regardless of route.

Yes, for certain allergens the evidence base favors shots. Allergy shots have stronger, more established efficacy data for cat dander, mold, and tree pollen, where sublingual data are thinner — partly because FDA-approved sublingual tablets do not exist for these allergens and compounded multi-allergen drops lack standardized phase-3 trials. This does not mean drops cannot help with these allergens, only that the supporting evidence is weaker and less certain. For grass and dust mite, by contrast, the routes appear comparable. The practical takeaway is that effectiveness should be judged allergen by allergen rather than as a single verdict, and your specific sensitizations should guide the choice.

The pivotal systematic review, Lin et al. 2013 in JAMA, which analyzed 63 randomized controlled trials, concluded there is moderate-grade evidence that sublingual immunotherapy reduces allergic rhinitis and rhinoconjunctivitis symptoms. Moderate grade means the evidence is reasonably consistent and clinically meaningful but not as definitive as high-grade evidence. Nine of 36 relevant studies showed greater than 40% symptom improvement. FDA-approved single-allergen tablets carry stronger phase-3 evidence, while compounded multi-allergen liquid drops are used off-label and lack that standardized base. Researchers therefore describe sublingual effectiveness as moderate and allergen-dependent rather than proven or guaranteed, and reputable sources avoid framing it as a sure outcome.

Immunotherapy of either route builds effect gradually, and durable benefit requires a sustained course. The GRASS trial (Scadding et al., JAMA 2017) showed that two years of either sublingual or subcutaneous treatment was insufficient to produce benefit that lasted after stopping, establishing three years as the threshold for durable disease modification. Many patients notice symptom improvement during the first year, but the fullest and most lasting benefit typically accrues over three to five years. Stopping early reduces durability. Because the timeline is similar for both routes, treatment duration is not a strong differentiator on effectiveness — both require multi-year commitment to reach and maintain their benefit.

No reputable source guarantees results from either route, and outcomes vary meaningfully between individuals. The evidence shows that many patients experience meaningful symptom reduction over a sustained course, but response depends on the allergen, the dose, adherence to daily or scheduled dosing, and individual immune factors. Some patients respond strongly, others modestly, and a minority see little change. The honest framing supported by the literature is that immunotherapy can reduce sensitivity over time and may provide long-term relief, not that it will cure allergies or guarantee a specific outcome. An allergist can give a realistic, individualized expectation based on your sensitization profile and history before you begin.